发布求助

文献互助智能选刊最新文献

Clinical advances in hematology & oncology : H&O最新文献

筛选

英文中文

Total neoadjuvant therapy approach in rectal adenocarcinoma. 直肠腺癌的全新辅助治疗方法。

IF 1

Clinical advances in hematology & oncology : H&O Pub Date : 2021-11-01

Sandra Kang, Christina Wu

{"title":"Total neoadjuvant therapy approach in rectal adenocarcinoma.","authors":"Sandra Kang, Christina Wu","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The treatment of locally advanced rectal cancer has improved over the years owing to advancements in surgical techniques and chemoradiation, developing into a multidisciplinary approach that has contributed to markedly reduced rates of local recurrence. Despite these advances, however, distant metastatic recurrence continues to be the main cause of rectal cancer-related death. Unfortunately, the former standard of care of neoadjuvant chemoradiation followed by surgery and adjuvant chemotherapy is still associated with significant morbidity and distant relapse rates. Many trials have studied the optimal sequence, timing, and duration of the individual components of treatment, more recently shifting both chemoradiation and systemic chemotherapy to the preoperative setting in an approach termed total neoadjuvant therapy (TNT). Some of the potential advantages of TNT include improved adherence to treatment, early treatment of micrometastases, and tumor downstaging, with the possibility of observation instead of surgery for those patients with a complete clinical response. This review provides the historical context for the shift to TNT in the treatment paradigm and discusses the critical clinical trials supporting the newer strategy. It also addresses the recent focus on the personalization of care that TNT makes possible by allowing the selective omission of radiation therapy and nonoperative management with a watch-and-wait strategy.</p>","PeriodicalId":520589,"journal":{"name":"Clinical advances in hematology & oncology : H&O","volume":" ","pages":"711-718"},"PeriodicalIF":1.0,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39646047","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

TNBC vs non-TNBC: A retrospective review of differences in mean age, family history, smoking history, and stage at diagnosis. TNBC与非TNBC：对平均年龄、家族史、吸烟史和诊断阶段的差异进行回顾性分析。

Clinical advances in hematology & oncology : H&O Pub Date : 2014-06-01

Khurram Tariq, Arezo Farhangi, Fauzia Rana

{"title":"TNBC vs non-TNBC: A retrospective review of differences in mean age, family history, smoking history, and stage at diagnosis.","authors":"Khurram Tariq, Arezo Farhangi, Fauzia Rana","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Purpose: </strong>This study was designed to compare mean age, ethnicity, smoking history, family history of breast cancer, and stage at diagnosis in patients with triple-negative breast cancer (TNBC) vs non-TNBC at an inner city university program.</p><p><strong>Methods: </strong>We reviewed data in our tumor registry on patients seen between January 2000 and December 2005, and identified a total of 445 patients with various subtypes of breast cancers. Of these, 342 patients met our study criteria. Thirty-nine patients had TNBC and 303 had non-TNBC.</p><p><strong>Results: </strong>The mean age at diagnosis was 59.87 ± 15.67 years for TNBC and 60.09 ± 13.98 years for non-TNBC (P=.9272). TNBC was more common in black than in white patients (58.97% vs 35.90%; OR, 2.755; P=.004), and non-TNBC was more common in white than in black patients (57.76% vs 39.27%). There was not a statistically significant difference in past or present smoking between the TNBC and non-TNBC patients (20.51% vs 27.72%; P=.4385). Family history of breast cancer was not statistically related to TNBC status: a positive family history was reported in 30.77% of TNBC patients vs 33.33% of non-TNBC patients (P=.8384), no family history was reported in 51.28% of TNBC patients vs 51.82% of non-TNBC patients, and family history was unknown in 17.95% of TNBC patients vs 14.85% of non-TNBC patients. Pathologic stage at the time of diagnosis was as follows for TNBC vs non-TNBC patients: stage 0, 15.79% vs 11.37% (P=.4332); stage I, 34.21% vs 30.98% (P=.6890); stage II, 28.98% vs 37.25% (P=.3205); stage III, 18.42% vs 17.25% (P=.8591); and stage IV, 3.63% vs 3.14% (P=.8651).</p><p><strong>Conclusion: </strong>We found that in our patient population, black women were significantly more likely to have TNBC than non-TNBC, and white women were more likely to have non-TNBC than TNBC.</p>","PeriodicalId":520589,"journal":{"name":"Clinical advances in hematology & oncology : H&O","volume":" ","pages":"377-81"},"PeriodicalIF":0.0,"publicationDate":"2014-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32487125","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mining the internet for drug information. 在互联网上挖掘药物信息。

IF 1

Clinical advances in hematology & oncology : H&O Pub Date : 2014-06-01

Nigam Shah

引用次数: 0

The balance is shifting away from screening. 这种平衡正在从筛选中转移。

IF 1

Clinical advances in hematology & oncology : H&O Pub Date : 2014-06-01

John Brodersen, Karsten Juhl Jørgensen

引用次数: 0

Malignancies associated with epstein-barr virus: pathobiology, clinical features, and evolving treatments. 与eb病毒相关的恶性肿瘤:病理生物学、临床特征和不断发展的治疗方法。

IF 1

Clinical advances in hematology & oncology : H&O Pub Date : 2014-06-01

Natalia Neparidze, Jill Lacy

引用次数: 0

Advances in the management of ITP in children and adults. 儿童和成人ITP治疗的进展。

IF 1

Clinical advances in hematology & oncology : H&O Pub Date : 2014-06-01

Paul Imbach

引用次数: 0

The argument for breast cancer screening. 关于乳腺癌筛查的争论。

IF 1

Clinical advances in hematology & oncology : H&O Pub Date : 2014-06-01

Otis W Brawley

引用次数: 0

Five Days At Memorial by Dr Sheri Fink. 雪莉·芬克博士的《五日纪念》。

IF 1

Clinical advances in hematology & oncology : H&O Pub Date : 2014-06-01

Bruce D Cheson

引用次数: 0

Maintenance therapy in metastatic colorectal cancer. 转移性结直肠癌的维持治疗。

IF 1

Clinical advances in hematology & oncology : H&O Pub Date : 2014-06-01

John L Marshall

引用次数: 0

Endocrine therapy for advanced breast cancer. 晚期乳腺癌的内分泌治疗。

IF 1

Clinical advances in hematology & oncology : H&O Pub Date : 2014-04-01

Payal D Shah, Maura N Dickler

{"title":"Endocrine therapy for advanced breast cancer.","authors":"Payal D Shah, Maura N Dickler","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The demonstrated efficacy of pharmacologic antiestrogen therapy in treating hormone receptor-positive breast cancer has changed the landscape of treatment for the majority of women with metastatic disease, providing them with a well-tolerated therapeutic alternative to surgical oophorectomy and chemotherapy. A multitude of clinical trials have evaluated the various endocrine agents alone or in combination. Studies have established ovarian suppression as key for the management of premenopausal metastatic breast cancer patients, and aromatase inhibitor therapy as first-line treatment for their postmenopausal counterparts. Fulvestrant (Faslodex, AstraZeneca) has also been found to be efficacious and has been studied in the first-line and second-line settings. De novo and acquired endocrine therapy resistance represent a major challenge to the ongoing treatment of patients with hormone receptor-positive disease; strategies to circumvent or delay resistance, including the use of combination endocrine therapy and endocrine therapy with agents targeting various growth-factor signaling pathways, represent an active area of investigation. This review provides a summary of the various landmark trials that have established our current standards of practice in the management of patients with hormone receptor-positive metastatic breast cancer. A discussion of future directions and ongoing studies is also provided. </p>","PeriodicalId":520589,"journal":{"name":"Clinical advances in hematology & oncology : H&O","volume":" ","pages":"214-23"},"PeriodicalIF":1.0,"publicationDate":"2014-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32487110","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

首页上一页

2
3
...
10

下一页尾页

联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1

京公网安备 11010802042870号

Book学术文献互助

Book学术文献互助群
群号：604180095

Book学术官方微信

小红书